#SA102 - Twitter Hashtag

about 1 year ago

🇨🇳 #3SBio announced that its #IND application for #SA102 has been approved by #NMPA for the treatment of relapsed or refractory multiple myeloma. SA102 is a CS1/BCMA dual-target CAR-T therapies developed by Wuhan Sian Medical Tech. In Dec. 2023, 3SBio and Sian signed a patent licensing agreement, granting 3SBio exclusive rights in Greater China for the development, registration, manufacturing, and commercialization of the drug. Previously, SA102 completed an IIT at Wuhan Union Hospital. The study results showed that among all 16 treated patients, 13 patients (ORR: 81%) achieved OR, reaching minimal residual disease (MRD) negativity, including -6 patients with sCR, -3 with very good partial response (VGPR), -4 PR. Additionally, among the 13 patients with detectable multiple myeloma (MM) cells in the bone marrow, the ORR and sCR rates were 100% and 46%, respectively. The median time to first achieving PR or better was 1.0 month (range: 0.5–1.0 months).

0

7

0

1

985

Car Play Life @CarPlayLife

almost 6 years ago

ICYMI: ATOTO #SA102 #Apple CarPlay, Android Auto & Media #Receiver #Review Enjoy our review of the #ATOTO SA102 Apple CarPlay, Android Auto & Media Receiver. RRP $149 from Amazon US or £169 from Amazon UK - Use coupon code ATOTOBT2 for 6% off https://t.co/BLsIqu5tR5 #video